TM Owner Bausch Health
Siliq 210mg/1.5mL Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Siliq 210mg/1.5mL (brodalumab) is an interleukin-17 receptor A antagonist given by subcutaneous injection, approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and who have failed to respond, or have lost response, to other systemic treatments.
- Because of the risk of suicidal thoughts and behaviour, Siliq is reserved for patients who have already tried other systemic psoriasis medicines.
- It is given as 210mg injections at weeks 0, 1 and 2, then every 2 weeks thereafter; if there is no adequate improvement after 12 to 16 weeks, treatment should be reconsidered.
- In the US, Siliq is only available through the restricted SILIQ REMS Program because of the suicide risk, and it is not approved for use in children.
Side Effects
- Siliq carries a boxed warning: suicidal ideation and behaviour, including completed suicides, have occurred in patients treated with Siliq, and it should be used with caution in anyone with a history of depression or suicidal thoughts, with prompt referral for new or worsening mood changes.
- Common side effects, each affecting more than 1% of patients, include joint pain, headache, fatigue, diarrhoea, throat pain, nausea, muscle aches, injection-site reactions, flu-like illness and low neutrophil counts.
- Serious risks include severe allergic reactions — seek emergency care for swelling of the face or throat or difficulty breathing — and a higher risk of fungal and other serious infections.
- Rotate injection sites and report any signs of infection, new depression, or suicidal thoughts to your healthcare provider immediately.
Precautions & Warnings
- Siliq is contraindicated in Crohn's disease and in anyone with a known hypersensitivity to brodalumab.
- Before starting, your healthcare provider will screen you for tuberculosis, since Siliq can reactivate latent TB infection; treatment should not begin during an active, clinically important infection.
- Siliq is only available in the US through the SILIQ REMS restricted-distribution programme because of the suicidal ideation and behaviour risk — prescribers, pharmacies and patients must all be enrolled.
- Avoid live vaccines while on Siliq.
- New or worsening eczema-like skin eruptions have been reported, sometimes months after starting treatment.
- Siliq is for subcutaneous injection only, given by a healthcare provider or self-injected at home after training — never inject into skin that is bruised, red, hard or affected by psoriasis.
Avoid Interactions
- Live vaccines should be avoided during treatment with Siliq, since it affects immune function; vaccinations should ideally be brought up to date before starting.
- Siliq can alter the activity of CYP450 liver enzymes that metabolise other medicines, so drugs with a narrow safety margin, such as warfarin or ciclosporin, may need closer monitoring or dose adjustment when Siliq is started or stopped.
- Tell your healthcare provider about all prescription and over-the-counter medicines, supplements and vaccinations, especially any recent or planned vaccines and any history of depression, mood changes or suicidal thoughts, before starting Siliq.
References
Frequently Asked Questions
Siliq (brodalumab) treats moderate-to-severe plaque psoriasis in adults who have not responded well to other systemic treatments. It blocks interleukin-17 receptor signalling to calm the overactive immune response that causes psoriasis plaques. Because of a suicide-risk warning, it is used only after other systemic therapies have been tried.
Siliq is given as a 210 mg subcutaneous injection at weeks 0, 1 and 2, then every 2 weeks after that. A healthcare provider gives the first doses; you may then self-inject at home after training, using the prefilled syringe, rotating injection sites each time.
Siliq carries a boxed warning for suicidal thoughts and behaviour, including completed suicides, so any new or worsening depression or mood change needs urgent medical attention. Common side effects include joint pain, headache, fatigue, diarrhoea and injection-site reactions. Serious infections and severe allergic reactions can also occur.
Avoid live vaccines while taking Siliq, and update your vaccinations before starting if possible. Siliq is not for people with Crohn's disease. Tell your prescriber about any depression, suicidal thoughts, or history of tuberculosis, since Siliq can reactivate latent TB and affect mood.
Siliq is only dispensed through the SILIQ REMS Program because of its boxed warning for suicidal ideation and behaviour. Prescribers, pharmacies and patients must all enrol, and patients receive a wallet card listing warning signs, ensuring everyone understands the risk before treatment starts.
Siliq is a long-term biologic treatment given every 2 weeks after the first three doses. If there is no meaningful improvement in psoriasis after 12 to 16 weeks, your healthcare provider will reconsider whether to continue. It is not approved for use in children.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
